Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19Research article Published on 2021-06-012022-10-05 Journal: European journal of internal medicine [Category] SARS, 치료법, [키워드] acute respiratory distress acute respiratory syndrome Administered administration adverse event Algorithm Anakinra applied Arm baseline Combination combination treatment comparator Coronavirus-2 Corticosteroid COVID-19 death rate Endpoint ferritin Hypothesis IL-1 IL-6 immune Immunomodulatory agent IMPROVE independent risk factors inflammatory process Intervention intubation lesson management median age moderate disease Mortality mortality rate Older age Patient patients patients with COVID-19 Respiratory failure Result SARS-CoV-2 Secondary infection severe respiratory failure Significant significantly higher single dose Standard-of-care survival syndrome Tocilizumab treated Treatment with COVID-19 [DOI] 10.1016/j.ejim.2021.03.026 [Article Type] Research article
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study중증 COVID-19 폐렴 및 중등도 과염증 환자에서 코르티코스테로이드 단독 또는 토실리주맙 치료 후 아나킨라. 후향적 코호트 연구Observational Study Published on 2021-06-012022-09-12 Journal: Internal and Emergency Medicine [Category] MERS, 임상, 진단, [키워드] 95% CI according to protocol adjusted hazard ratio Admission age Anakinra analyzed appear carried CD4 Characteristics clinical Clinical course Clinical severity Corticosteroid corticosteroid pulse COVID-19 Cytokine storm syndrome death died Evidence hyperinflammation hyperinflammatory state IMPROVE infectious complication Infectious complications intensive care Laboratory management Methylprednisolone moderate Mortality Observational cohort study Patient patients with moderate Prognosis pulse receiving receptor reduced risk retrospective retrospective cohort study Severe COVID-19 pneumonia Standard therapy Tocilizumab tocilizumab therapy Treatment treatment with anakinra [DOI] 10.1007/s11739-020-02600-z PMC 바로가기 [Article Type] Observational Study
Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agentsReview Published on 2021-05-042022-10-29 Journal: Pediatric Rheumatology Online Journal [Category] COVID-19, [키워드] administration Adults Anakinra anti-IL-1 anti-IL-6 approach biologic agents canakinumab caused children Chloroquine clinical experience Colchicine condition contributing to coronavirus COVID-19 Cytokine storm defined develop disease course disease phenotype disease stage drug drugs dysregulation Evidence expression Hydroxychloroquine immune immune system impairment induce Inflammatory inflammatory mediator less macrophage activation syndrome manifestation Mild MIS-C multisystem inflammatory syndrome in children pediatric Pediatric patients pharmacological representing resulting role SARS-CoV-2 severe coronavirus disease severe disease supported syndrome systemic manifestation the disease the timing Therapeutic approach Tocilizumab Treatment [DOI] 10.1186/s12969-021-00559-5 PMC 바로가기 [Article Type] Review
Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google TrendsArticle Published on 2021-05-012023-07-05 Journal: Clinical Rheumatology [Category] SARS, [키워드] Anakinra Colchicine Google search Hydroxychloroquine Internet Tocilizumab [DOI] 10.1007/s10067-020-05490-w PMC 바로가기
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors에마팔루맙은 아나킨라, 토실리주맙 및 야누스 키나제 억제제에 내성이 있는 COVID-19로 인한 불응성, 재발성 및 진행성 사이토카인 폭풍에 대해 생명을 구할 수 있습니까?Article Published on 2021-05-012022-09-12 Journal: Indian journal of pharmacology [Category] 진단, [키워드] Anakinra Antiviral Can caused cell types Clinical course coronavirus COVID-19 cytokine Cytokine storm Cytokine storms Defense drug emapalumab human immunoglobulin G1 IFN-γ IFNs IL-1 IL-6 antagonist IMPROVE inhibitor intensive care interferon Jak jak inhibitors Janus kinase Janus kinase inhibitor monoclonal antibody Mortality Patient released SARS-CoV-2 the cytokine storm the patient Tocilizumab treated [DOI] 10.4103/ijp.IJP_615_20 PMC 바로가기 [Article Type] Article
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation호흡기 장애, 중증 폐렴 및 과염증이 있는 COVID-19 환자에서 IL-1 및 IL-6 차단에 대한 반응 예측Clinical Trial Published on 2021-04-292022-08-13 Journal: Frontiers in Immunology [Category] MERS, SARS, 임상, 진단, [키워드] administration Anakinra anti-cytokine therapy anti-cytokine therapy initiation coronavirus coronavirus disease Coronavirus disease-19 COVID-19 COVID-19 patient Cytokines Efficacy Evidence evidence of Follow-up hyper-inflamed COVID-19 patient hyper-inflamed COVID-19 patients identify IL-1 IL-6 IL-6 blockade IL-6 blocking inhibitor initiated interleukin interleukin (IL)-1 interleukin-1 interleukin-6 median Mortality objective PaO Patient patients treated pro-inflammatory cytokine pro-inflammatory cytokines provided reduced respiratory Respiratory failure respiratory impairment response Restraining maladaptive inflammation Result sarilumab SARS-CoV-2 selective severe coronavirus disease severe hyper-inflamed COVID-19 patients severe respiratory failure significantly higher Standard of care Standard therapy stratified survival survival rate therapeutic therapy Tocilizumab treat treated Treatment treatment failure treatment initiation treatment with biologics window [DOI] 10.3389/fimmu.2021.675678 PMC 바로가기 [Article Type] Clinical Trial
Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatmentsCase Report Published on 2021-04-052022-10-04 Journal: IDCases [Category] 치료법, [키워드] Anakinra complication of COVID-19 Course COVID-19 cytomegalovirus Cytomegalovirus infections Dexamethasone iatrogenic immune dysregulation immunomodulators Immunosuppression immunosuppressive Immunosuppressive treatment Proctitis Rectal diseases risk Severe COVID-19 pneumonia treated [DOI] 10.1016/j.idcr.2021.e01111 PMC 바로가기 [Article Type] Case Report
Tackling Immune Pathogenesis of COVID-19 through Molecular PharmaceuticsPerspective Published on 2021-04-052022-10-28 Journal: Pharmaceutics [Category] COVID-19, [키워드] Anakinra anti-inflammatory agent anti-inflammatory strategy Antiviral benefit clinical study Clinical use Coronavirus disease-19 COVID-19 COVID-19 patients drug Drug discovery Drug interactions effective effective therapy Efficacy immunomodulatory increased risk Infection inflammatory pathway Injury Intervention knowledge Medicines molecular molecular pharmaceutics pandemic pathway Perspective Pharmaceutics Prevent Repurposed drug required Safe tested therapy treat treatment approaches tryptophan metabolites [DOI] 10.3390/pharmaceutics13040494 PMC 바로가기 [Article Type] Perspective
IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational StudyObservational Study Published on 2021-04-012022-10-05 Journal: Journal of immunology (Baltimore, Md. : 1950) [Category] SARS, 임상, [키워드] 95% confidence interval acute respiratory distress adverse event Anakinra Analysis antagonist ARDS baseline Cohort Control controls coronavirus disease COVID-19 COVID-19 ARDS patient evaluated groups IL-1 IL-1 receptor antagonist immunomodulatory invasive Italy Odds ratio off-label Patient patients with ARDS positive airway pressure primary end point receive respiratory significantly higher stratified Support supported survival syndrome therapeutic option treated Treatment was obtained with COVID-19 [DOI] 10.4049/jimmunol.2001126 PMC 바로가기 [Article Type] Observational Study
Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumoniaControlled Clinical Trial Published on 2021-04-012022-10-05 Journal: The Journal of Allergy and Clinical Immunology [Category] SARS, 임상, 치료법, [키워드] adjusted adjusted hazard ratio Admission Anakinra anti-inflammatory treatment Anticoagulants Antiviral baseline cohort study Combination coronavirus disease covariates COVID-19 COVID-19 pneumonia Cox model Cytokine storm early treatment Efficacy Efficacy and safety evaluated glucocorticoid Glucocorticoids High dose Hydroxychloroquine IL-1 Inflammatory response intravenous intravenous methylprednisolone Mortality Patient patients patients with COVID-19 performed Pneumonia receive receiving reduced retrospective Severe COVID-19 pneumonia single-center Standard of care survival Tocilizumab Treatment were used [DOI] 10.1016/j.jaci.2021.01.024 PMC 바로가기 [Article Type] Controlled Clinical Trial